Ana Alfirevic is Reader in Pharmacology with the primary focus on pharmacogenetics and molecular pharmacology research. She is working on several projects on identification of genetic predisposing factors for adverse drug reactions including drug-induced hypersensitivity, hepatotoxicity, antipsychotic drug-induced agranulocytosis and statin-induced myotoxicity using high throughput genotyping and sequencing technologies. Recently, she has started several pharmacology and systems biology projects in reproductive medicine and pregnancy. She leads a work package on multiomic approaches to preterm birth within the Harris Centre for Preterm Birth funded by Wellbeing of Women, and also leads the PREDICTION-ADR EU grant that investigates predisposing genetic factors to statin-induced myopathy. Common to these research themes is the aim to generate large amount of omics data integrated with clinical data to identify biomarkers that may be utilized in clinical practice for patient benefit.
In addition, she is involved in public health research via the National Institute of Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (CLAHRC NWC), where she is a co-lead for the Delivering Personalised Health and Care theme. The overarching aim of the programme is to tackle health inequalities.

https://www.liverpool.ac.uk/translational-medicine/staff/ana-alfirevic/